Saltar al contenido
Merck

Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease.

Science translational medicine (2015-01-16)
Angharad M Roberts, James S Ware, Daniel S Herman, Sebastian Schafer, John Baksi, Alexander G Bick, Rachel J Buchan, Roddy Walsh, Shibu John, Samuel Wilkinson, Francesco Mazzarotto, Leanne E Felkin, Sungsam Gong, Jacqueline A L MacArthur, Fiona Cunningham, Jason Flannick, Stacey B Gabriel, David M Altshuler, Peter S Macdonald, Matthias Heinig, Anne M Keogh, Christopher S Hayward, Nicholas R Banner, Dudley J Pennell, Declan P O'Regan, Tan Ru San, Antonio de Marvao, Timothy J W Dawes, Ankur Gulati, Emma J Birks, Magdi H Yacoub, Michael Radke, Michael Gotthardt, James G Wilson, Christopher J O'Donnell, Sanjay K Prasad, Paul J R Barton, Diane Fatkin, Norbert Hubner, Jonathan G Seidman, Christine E Seidman, Stuart A Cook
RESUMEN

The recent discovery of heterozygous human mutations that truncate full-length titin (TTN, an abundant structural, sensory, and signaling filament in muscle) as a common cause of end-stage dilated cardiomyopathy (DCM) promises new prospects for improving heart failure management. However, realization of this opportunity has been hindered by the burden of TTN-truncating variants (TTNtv) in the general population and uncertainty about their consequences in health or disease. To elucidate the effects of TTNtv, we coupled TTN gene sequencing with cardiac phenotyping in 5267 individuals across the spectrum of cardiac physiology and integrated these data with RNA and protein analyses of human heart tissues. We report diversity of TTN isoform expression in the heart, define the relative inclusion of TTN exons in different isoforms (using the TTN transcript annotations available at http://cardiodb.org/titin), and demonstrate that these data, coupled with the position of the TTNtv, provide a robust strategy to discriminate pathogenic from benign TTNtv. We show that TTNtv is the most common genetic cause of DCM in ambulant patients in the community, identify clinically important manifestations of TTNtv-positive DCM, and define the penetrance and outcomes of TTNtv in the general population. By integrating genetic, transcriptome, and protein analyses, we provide evidence for a length-dependent mechanism of disease. These data inform diagnostic criteria and management strategies for TTNtv-positive DCM patients and for TTNtv that are identified as incidental findings.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Diclorometano, suitable for HPLC, ≥99.8%, contains amylene as stabilizer
Sigma-Aldrich
Diclorometano, contains 40-150 ppm amylene as stabilizer, ACS reagent, ≥99.5%
Sigma-Aldrich
Diclorometano, HPLC Plus, for HPLC, GC, and residue analysis, ≥99.9%, contains 50-150 ppm amylene as stabilizer
Sigma-Aldrich
Diclorometano, ACS reagent, ≥99.5%, contains 40-150 ppm amylene as stabilizer
Sigma-Aldrich
Diclorometano, anhydrous, ≥99.8%, contains 40-150 ppm amylene as stabilizer
Sigma-Aldrich
Diclorometano, puriss. p.a., ACS reagent, reag. ISO, ≥99.9% (GC)
Sigma-Aldrich
Diclorometano, puriss., meets analytical specification of Ph. Eur., NF, ≥99% (GC)
Sigma-Aldrich
Diclorometano, ACS reagent, ≥99.5%, contains 40-150 ppm amylene as stabilizer
Supelco
Diclorometano, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Diclorometano, biotech. grade, 99.9%, contains 40-150 ppm amylene as stabilizer
Supelco
Diclorometano, analytical standard
Supelco
Diclorometano, ≥99.9%
Supelco
Dichloromethane solution, contains 10 % (v/v) methanol
Sigma-Aldrich
Diclorometano, JIS special grade, ≥99.0%
Sigma-Aldrich
Thallium(III) nitrate trihydrate
Sigma-Aldrich
Diclorometano, SAJ first grade, ≥99.0%
Sigma-Aldrich
Diclorometano, suitable for HPLC, ≥99.9%, contains 40-150 ppm amylene as stabilizer
Supelco
Diclorometano, Selectophore, ≥99.5%